查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1755938

2032 年黴漿菌檢測市場預測：按產品、技術、應用、最終用戶和地區進行的全球分析

Mycoplasma Testing Market Forecasts to 2032 - Global Analysis By Product, Technique, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球黴漿菌檢測市場預計在 2025 年達到 11.9807 億美元，預計到 2032 年將達到 25.993 億美元，預測期內的複合年成長率為 11.7%。

黴漿菌檢測是製藥和生物技術生產中重要的品管方法，用於確定細胞培養物、疫苗和生物製藥是否受到黴漿菌污染。黴漿菌是一種難以用傳統微生物學方法鑑定的細菌，因為它沒有細胞壁，並且對許多常見抗生素具有抗藥性。黴漿菌污染會改變細胞的代謝方式，導致其停止生長，進而影響產品安全和實驗結果。此外，各種檢測技術，包括酵素連結免疫吸附測定、培養方法和PCR，可以確保生物製品和研究材料的真實性和安全性。

據 ATCC 稱，連續細胞培養中的黴漿菌污染率為 15-35%，而原代細胞培養中的支原體污染率至少為 1%。

基於細胞的研究的興起

由於哺乳動物細胞培養在藥物研發、癌症研究、毒理學、疫苗開發、個人化醫療等領域的廣泛應用，黴漿菌檢測已成為學術和商業性實驗室的必需環節。錯誤的結論、扭曲的實驗數據、改變的基因表現以及降低的可重複性都可能由受污染的細胞株造成。這種高頻率凸顯了常規篩檢程序對於維持研究結果完整性的重要性。為了保持實驗系統的準確性和可靠性，黴漿菌檢測已成為大多數分子生物學和生物醫學實驗室的常規檢測。

昂貴的先進測試技術

數位PCR、即時PCR和新一代定序（NGS）等先進檢測技術高成本，是限制黴漿菌檢測市場發展的主要因素之一。儘管這些技術速度更快、靈敏度更高，但它們需要在專用工具、化學品和技術人員方面投入大量的初始資金。開發中國家的中小型生物製藥公司、學術機構和低預算實驗室無法負擔這些系統，從而限制了常規黴漿菌檢測的普及。此外，這些先進儀器的頻繁維護、校準和驗證也增加了營運成本。

高性能系統建置與自動化

建構高性能自動化黴漿菌檢測平台，為解決生物製造中的可擴展性和效率問題帶來巨大機會。隨著批次數量的增加、嚴格的放行計畫和檢測頻率的提高，生物製藥公司正在尋求能夠減少手動任務和周轉時間，同時提高可重複性的解決方案。此外，大型合約生產與製造組織 (CDMO) 和生技藥品製造商將對能夠提供與其製造執行系統 (MES) 和品管系統 (QMS) 相容的整合黴漿菌檢測模組的公司抱有濃厚的興趣。

其他污染檢測技術的激烈競爭

具有多重檢測能力和廣泛覆蓋範圍的替代性微生物污染檢測技術正給市場帶來越來越大的壓力。近期，使用新一代定序 (NGS) 和元基因組分析的平台可以在一次檢測中同時檢測多種細菌、病毒、真菌和黴漿菌。儘管這些綜合技術尚處於起步階段，但它們正受到尋求全面污染監測系統的主要生物製造商的青睞。此外，如果傳統的單標靶黴漿菌檢測套組無法跟上整合式多參數解決方案的步伐，它們可能會失去市場佔有率。

COVID-19的影響

COVID-19 疫情以多種方式影響了黴漿菌檢測市場。一方面，全球供應鏈中斷和實驗室進入受限導致常規檢測業務暫時停滯，尤其是在學術機構和小型生物技術公司。許多與 COVID-19 無關的臨床試驗和生技藥品生產被推遲，因此污染檢測的緊迫性有所降低。然而，疫情也凸顯了生技藥品和疫苗生產中強力的品管的重要性，促使人們增加了對品質保證和生技藥品基礎設施（包括黴漿菌檢測）的投資。

預計聚合酵素鏈鎖反應（PCR）部分在預測期內將佔據最大佔有率。

聚合酵素鏈鎖反應(PCR) 因其卓越的靈敏度、特異性、快速的周轉時間以及識別多種黴漿菌的能力，預計將在預測期內佔據最大的市場佔有率。在生技藥品生產和細胞治療程序中，PCR 被認為是污染檢測的黃金標準。然而，PCR 比酵素結合免疫吸附試驗 (ELISA) 更靈敏，後者因其經濟實惠和易於使用而廣受好評。研究中通常採用直接法和間接法。

預計細胞株測試部分將在預測期內達到最高複合年成長率

預計細胞株測試領域將在預測期內達到最高成長率。這一成長源於哺乳動物細胞株在疫苗、單株抗體和生技藥品生產中日益廣泛的應用，而這些生產過程都需要嚴格的污染篩檢。病毒檢測雖然對生物安全至關重要，但由於對病原體的關注度不斷提高以及對先進療法的監管需求，其應用也在穩步成長。生產終端細胞測試雖然不如上游細胞株測試常見，但對於確認批次無菌性仍然至關重要。由於細胞株測試已被整合到生物生產的早期階段，它將繼續成為成長最快的應用。

佔比最高的地區

預計北美將在預測期內佔據最大的市場佔有率。這得益於強勁的研發支出、成熟的生物製藥產業以及FDA等組織支持的嚴格監管標準。該地區的許多CRO、CDMO和生技藥品製造商都要求在生產的每個階段定期進行污染篩檢。完善的法律規範、對細胞和基因治療的持續投資以及先進分子診斷技術的廣泛應用，都有助於鞏固市場主導地位。此外，關鍵參與企業的存在和強大的學術研究支持早期採用尖端測試解決方案和技術進步，從而確保北美在全球市場佔據主導地位。

複合年成長率最高的地區

預計亞太地區將在預測期內實現最高的複合年成長率。生技藥品需求的不斷成長、中國、印度和日本等國生產能力的提升以及製藥和生物技術研究投資的不斷增加是推動這一快速成長的關鍵因素。由於監管更加嚴格以及對污染控制意識的不斷增強，黴漿菌檢測服務和產品在這些國家也變得越來越普及。此外，該地區新興國家提供的成本優勢也推動了市場擴張，使其成為受託製造廠商(CMO) 和委外研發機構(CRO) 的理想之地。

免費客製化服務

訂閱此報告的客戶可享有以下免費自訂選項之一：

  • 公司簡介
    • 對其他市場參與企業（最多 3 家公司）進行全面分析
    • 主要企業的SWOT分析（最多3家公司）
  • 地理細分
    • 根據客戶興趣對主要國家進行市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 透過產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 研究範圍
  • 調查方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 研究途徑
  • 研究材料
    • 主要研究資料
    • 二手研究資料
    • 先決條件

第3章市場走勢分析

  • 介紹
  • 驅動程式
  • 限制因素
  • 機會
  • 威脅
  • 產品分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • COVID-19的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買家的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球黴漿菌檢測市場（按產品）

  • 介紹
  • 裝置
  • 套件和試劑
    • PCR檢測
    • 核酸檢測試劑套件
    • 染色
    • 拆卸套件
    • 標準與管理
  • 服務

6. 全球黴漿菌檢測市場（按技術）

  • 介紹
  • 聚合酵素鏈鎖反應（PCR）
  • 酵素免疫分析法（ELISA）
  • 直接分析
  • 間接測定
  • 微生物培養技術
  • 酵素法
  • DNA染色

7. 全球黴漿菌檢測市場（按應用）

  • 介紹
  • 細胞株測試
  • 病毒檢測
  • 已停止電池測試
  • 其他

8. 全球黴漿菌檢測市場（依最終用戶）

  • 介紹
  • 學術研究所
  • 細胞庫
  • 合約研究組織
  • 製藥和生物技術公司
  • 其他

9. 全球黴漿菌檢測市場（按地區）

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第10章 重大進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章 公司概況

  • Thermo Fisher Scientific, Inc.
  • Becton, Dickinson, and Company（BD）
  • Eurofins Scientific
  • Agilent Technologies
  • F. Hoffmann-La Roche Ltd.
  • Clongen Laboratories, LLC
  • Bionique Testing Laboratories, Inc.
  • Lonza Group Ltd.
  • Merck KGaA
  • Charles River Laboratories International, Inc.
  • Bio-Rad Laboratories, Inc.
  • PromoCell GmbH
  • Norgen BIoTek Corp.
  • Sartorius AG
  • Minerva Biolabs GmbH
Product Code: SMRC29832

According to Stratistics MRC, the Global Mycoplasma Testing Market is accounted for $1198.07 million in 2025 and is expected to reach $2599.30 million by 2032 growing at a CAGR of 11.7% during the forecast period. Mycoplasma testing is a crucial quality control method used in pharmaceutical and biotechnology production to find out whether cell cultures, vaccines, and biopharmaceutical products are contaminated with Mycoplasma. Because they lack a cell wall, mycoplasmas are a class of bacteria that are difficult to identify using conventional microbiological techniques and resistant to many common antibiotics. Mycoplasma contamination can change how cells metabolize, stop them from growing, and affect the safety of products or the outcomes of experiments. Moreover, the dependability and security of biological products and research materials are guaranteed by a variety of testing techniques, including enzymatic assays, culture methods, and PCR.

According to ATCC, Mycoplasma contamination of continuous cell cultures ranges from 15-35%, with primary cell cultures exhibiting a minimum 1% contamination rate, and emphasizes routine testing throughout production to ensure both safety and experimental reliability.

Market Dynamics:

Driver:

Growing use of research based on cells

Mycoplasma testing is now essential in both academic and commercial labs due to the extensive use of mammalian cell cultures in drug discovery, cancer research, toxicology, vaccine development, and personalized medicine. Erroneous conclusions, distorted experimental data, changed gene expression, and impaired reproducibility can all result from contaminated cell lines. This high frequency emphasizes how crucial routine screening procedures are to maintaining the integrity of research findings. To preserve the caliber and dependability of experimental systems, Mycoplasma testing has become commonplace in the majority of molecular biology and biomedical labs.

Restraint:

Expensive advanced testing techniques

The high cost of sophisticated detection technologies like digital PCR, real-time PCR, and next-generation sequencing (NGS) is one of the main factors limiting the market for Mycoplasma testing. Despite having higher speed and sensitivity, these techniques necessitate a large initial investment in specialized tools, chemicals, and skilled workers. The adoption of routine Mycoplasma testing is often limited by the inability of small and medium-sized biopharmaceutical companies, academic institutions, and low-budget laboratories in developing nations to afford these systems. Moreover, frequent maintenance, calibration, and validation of these sophisticated instruments raise operating costs.

Opportunity:

Creation of high-throughput systems and automation

The creation of high-throughput, automated Mycoplasma testing platforms offers a significant chance to solve issues with biomanufacturing's scalability and efficiency. Biopharma firms are looking for solutions that decrease manual handling and turnaround time while enhancing reproducibility due to rising batch volumes, strict release schedules, and an increase in testing frequency. Additionally, large-scale CDMOs and biologics manufacturers will be very interested in companies that can provide integrated Mycoplasma detection modules that are compatible with manufacturing execution systems (MES) and quality management systems (QMS).

Threat:

Strong competition from other techniques for contamination detection

Alternative microbial contamination detection technologies with multiplexing capabilities or wider coverage are putting more and more pressure on the market. Many bacteria, viruses, fungi, and mycoplasma can all be detected simultaneously in a single assay by more recent platforms that use next-generation sequencing (NGS) or metagenomic analysis. Despite their infancy, these all-encompassing techniques are gaining traction with major biomanufacturers looking for comprehensive contamination monitoring systems. Furthermore, the failure of conventional and single-target Mycoplasma testing kits to keep up with integrated and multiparametric solutions could result in a loss of market share.

Covid-19 Impact:

The COVID-19 pandemic affected the mycoplasma testing market in a variety of ways. On the one hand, routine testing operations were momentarily slowed, particularly in academic and small biotech settings, by the disruption of global supply chains and limitations on lab access. There was less of an urgent need for contamination testing because many clinical trials and the production of biologics unrelated to COVID-19 were postponed. But the pandemic also brought to light the significance of strong quality control in the manufacturing of biologics and vaccines, which led to a rise in investments in quality assurance, including mycoplasma testing, and biologics infrastructure.

The polymerase chain reaction (PCR) segment is expected to be the largest during the forecast period

The polymerase chain reaction (PCR) segment is expected to account for the largest market share during the forecast period because of its great sensitivity, specificity, quick turnaround time, and capacity to identify a variety of Mycoplasma species. In the production of biologics and cell therapy procedures, PCR is regarded as the gold standard for contamination detection. However, PCR is more sensitive than enzyme-linked immunosorbent assay (ELISA), which is praised for its affordability and ease of use. In research contexts, both direct and indirect assays are commonly employed.

The cell line testing segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the cell line testing segment is predicted to witness the highest growth rate. The growing use of mammalian cell lines in the production of vaccines, monoclonal antibodies, and biologics-all of which need stringent contamination screening-is what is causing this growth. Despite being crucial for biosafety, virus testing is steadily increasing because of its wider focus on pathogens and the regulatory need for advanced therapies. Although end-of-production cell testing is less common than upstream cell line testing, it is still essential for verifying batch sterility. Because cell line testing is integrated into early stages of bioproduction, it continues to be the application with the fastest rate of growth.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, driven by its strong R&D expenditures, established biopharmaceutical sector, and strict regulatory standards upheld by organizations such as the FDA. Many CROs, CDMOs, and biologics manufacturers in the area need regular contamination screening at every stage of production. A developed regulatory framework, growing investments in cell and gene therapies, and the widespread use of sophisticated molecular diagnostics all contribute to market dominance. Furthermore, the presence of important players and strong academic research supports early adoption of cutting-edge testing solutions and technological advancement, securing North America's dominant position in the global market.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR. The growing demand for biologics, growing manufacturing capacities in nations like China, India, and Japan, and growing investments in pharmaceutical and biotechnology research are the main drivers of this quick growth. Mycoplasma testing services and products are also becoming more popular in these nations due to stricter regulations and increased awareness of contamination control. Additionally, propelling market expansion are the cost advantages that the region's emerging economies provide, which make it a favored location for contract manufacturing organizations (CMOs) and contract research organizations (CROs).

Key players in the market

Some of the key players in Mycoplasma Testing Market include Thermo Fisher Scientific, Inc., Becton, Dickinson, and Company (BD), Eurofins Scientific, Agilent Technologies, F. Hoffmann-La Roche Ltd., Clongen Laboratories, LLC, Bionique Testing Laboratories, Inc., Lonza Group Ltd., Merck KGaA, Charles River Laboratories International, Inc., Bio-Rad Laboratories, Inc, PromoCell GmbH, Norgen Biotek Corp., Sartorius AG and Minerva Biolabs GmbH.

Key Developments:

In February 2025, Thermo Fisher Scientific Inc. has announced a 10-year virtual power purchasing agreement (VPPA) with renewable energy developer, X-ELIO. The agreement aims to increase the access to renewable electricity across the healthcare and pharmaceutical supply chains. Expected to be operational in early 2026, the project will include a cohort of three partners across both sectors.

In October 2024, BD (Becton, Dickinson and Company) announced it has reached an agreement to resolve the vast majority of its existing hernia litigation. Terms of the settlement agreement, which are confidential, include cases in both the Rhode Island consolidated litigation and the federal multidistrict litigation in Ohio.

In October 2024, Eurofins Scientific has reached an agreement with SYNLAB to acquire its clinical diagnostics operations in Spain. The transaction is subject to customary conditions, including regulatory approvals, and is expected to close in 2025. SYNLAB's clinical diagnostics operations in Spain provide clinical diagnostics testing, including genetics and anatomical pathology services, throughout the country, achieving revenues of approximately €140m in 2023.

Products Covered:

  • Instruments
  • Kits & Reagents
  • Service

Techniques Covered:

  • Polymerase Chain Reaction (PCR)
  • Enzyme-linked Immunosorbent Assay (ELISA)
  • Direct Assay
  • Indirect Assay
  • Microbial Culture Techniques
  • Enzymatic Methods
  • DNA Staining

Applications Covered:

  • Cell Line Testing
  • Virus Testing
  • End of Production Cells Testing
  • Other Applications

End Users Covered:

  • Academic Research Institutes
  • Cell Banks
  • Contract Research Organizations
  • Pharmaceutical & Biotechnology Companies
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Mycoplasma Testing Market, By Product

  • 5.1 Introduction
  • 5.2 Instruments
  • 5.3 Kits & Reagents
    • 5.3.1 PCR Assays
    • 5.3.2 Nucleic Acid Detection Kits
    • 5.3.3 Stains
    • 5.3.4 Elimination Kits
    • 5.3.5 Standards & Controls
  • 5.4 Service

6 Global Mycoplasma Testing Market, By Technique

  • 6.1 Introduction
  • 6.2 Polymerase Chain Reaction (PCR)
  • 6.3 Enzyme-linked Immunosorbent Assay (ELISA)
  • 6.4 Direct Assay
  • 6.5 Indirect Assay
  • 6.6 Microbial Culture Techniques
  • 6.7 Enzymatic Methods
  • 6.8 DNA Staining

7 Global Mycoplasma Testing Market, By Application

  • 7.1 Introduction
  • 7.2 Cell Line Testing
  • 7.3 Virus Testing
  • 7.4 End of Production Cells Testing
  • 7.5 Other Applications

8 Global Mycoplasma Testing Market, By End User

  • 8.1 Introduction
  • 8.2 Academic Research Institutes
  • 8.3 Cell Banks
  • 8.4 Contract Research Organizations
  • 8.5 Pharmaceutical & Biotechnology Companies
  • 8.6 Other End Users

9 Global Mycoplasma Testing Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Thermo Fisher Scientific, Inc.
  • 11.2 Becton, Dickinson, and Company (BD)
  • 11.3 Eurofins Scientific
  • 11.4 Agilent Technologies
  • 11.5 F. Hoffmann-La Roche Ltd.
  • 11.6 Clongen Laboratories, LLC
  • 11.7 Bionique Testing Laboratories, Inc.
  • 11.8 Lonza Group Ltd.
  • 11.9 Merck KGaA
  • 11.10 Charles River Laboratories International, Inc.
  • 11.11 Bio-Rad Laboratories, Inc.
  • 11.12 PromoCell GmbH
  • 11.13 Norgen Biotek Corp.
  • 11.14 Sartorius AG
  • 11.15 Minerva Biolabs GmbH

List of Tables

  • Table 1 Global Mycoplasma Testing Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Mycoplasma Testing Market Outlook, By Product (2024-2032) ($MN)
  • Table 3 Global Mycoplasma Testing Market Outlook, By Instruments (2024-2032) ($MN)
  • Table 4 Global Mycoplasma Testing Market Outlook, By Kits & Reagents (2024-2032) ($MN)
  • Table 5 Global Mycoplasma Testing Market Outlook, By PCR Assays (2024-2032) ($MN)
  • Table 6 Global Mycoplasma Testing Market Outlook, By Nucleic Acid Detection Kits (2024-2032) ($MN)
  • Table 7 Global Mycoplasma Testing Market Outlook, By Stains (2024-2032) ($MN)
  • Table 8 Global Mycoplasma Testing Market Outlook, By Elimination Kits (2024-2032) ($MN)
  • Table 9 Global Mycoplasma Testing Market Outlook, By Standards & Controls (2024-2032) ($MN)
  • Table 10 Global Mycoplasma Testing Market Outlook, By Service (2024-2032) ($MN)
  • Table 11 Global Mycoplasma Testing Market Outlook, By Technique (2024-2032) ($MN)
  • Table 12 Global Mycoplasma Testing Market Outlook, By Polymerase Chain Reaction (PCR) (2024-2032) ($MN)
  • Table 13 Global Mycoplasma Testing Market Outlook, By Enzyme-linked Immunosorbent Assay (ELISA) (2024-2032) ($MN)
  • Table 14 Global Mycoplasma Testing Market Outlook, By Direct Assay (2024-2032) ($MN)
  • Table 15 Global Mycoplasma Testing Market Outlook, By Indirect Assay (2024-2032) ($MN)
  • Table 16 Global Mycoplasma Testing Market Outlook, By Microbial Culture Techniques (2024-2032) ($MN)
  • Table 17 Global Mycoplasma Testing Market Outlook, By Enzymatic Methods (2024-2032) ($MN)
  • Table 18 Global Mycoplasma Testing Market Outlook, By DNA Staining (2024-2032) ($MN)
  • Table 19 Global Mycoplasma Testing Market Outlook, By Application (2024-2032) ($MN)
  • Table 20 Global Mycoplasma Testing Market Outlook, By Cell Line Testing (2024-2032) ($MN)
  • Table 21 Global Mycoplasma Testing Market Outlook, By Virus Testing (2024-2032) ($MN)
  • Table 22 Global Mycoplasma Testing Market Outlook, By End of Production Cells Testing (2024-2032) ($MN)
  • Table 23 Global Mycoplasma Testing Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 24 Global Mycoplasma Testing Market Outlook, By End User (2024-2032) ($MN)
  • Table 25 Global Mycoplasma Testing Market Outlook, By Academic Research Institutes (2024-2032) ($MN)
  • Table 26 Global Mycoplasma Testing Market Outlook, By Cell Banks (2024-2032) ($MN)
  • Table 27 Global Mycoplasma Testing Market Outlook, By Contract Research Organizations (2024-2032) ($MN)
  • Table 28 Global Mycoplasma Testing Market Outlook, By Pharmaceutical & Biotechnology Companies (2024-2032) ($MN)
  • Table 29 Global Mycoplasma Testing Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.